Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.60 |
| ▸ | MAOA | P21397 | 6/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21198165 | 1.00 | MAOB (0.60) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL568146 | 1.00 | MAOB (0.60) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL566991 | 0.95 | MAOB (0.60) | MAOBMAOAHTR6NPC1ALDH1A1 | |
| SCHEMBL566990 | 0.95 | MAOB (0.60) | MAOBMAOAHTR6NPC1ALDH1A1 | |
| SCHEMBL21198139 | 0.87 | MAOB (0.60) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL21198798 | 0.87 | MAOB (0.60) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL9211093 | 0.87 | MAOB (0.60) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL21198799 | 0.87 | MAOB (0.60) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL9694749 | 0.83 | ALOX5 (0.65) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL9211460 | 0.82 | MAOB (0.60) | MAOBMAOAHTR6NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| EP-3743414-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145719-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| EP-2941427-B1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PF MEDICAMENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2015-11-26 | — | — | US | disclosed |
| EP-2941427-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Pierre Fabre Médicament (FR) | 2015-11-11 | — | — | EP | disclosed |
| EP-2176252-B1 | 2, 3-DIHYDROBENZO[1, 4]DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORP (FI) | 2014-09-03 | — | — | EP | disclosed |
| US-8809536-B2 | 2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases | ORION CORPORATION (FI) | 2014-08-19 | — | — | US | disclosed |
| WO-2014106660-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2014-07-10 | — | — | WO | disclosed |
| US-20140179926-A1 | 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | ORION CORPORATION (FI) | 2014-06-26 | — | — | US | disclosed |
| US-8697723-B2 | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases | ORION CORPORATION (FI) | 2014-04-15 | — | — | US | disclosed |
| US-20130281486-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | ORION CORP (FI) | 2013-10-24 | — | — | US | disclosed |
| US-8492549-B2 | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous systeme diseases | ORION CORPORATION (FI) | 2013-07-23 | — | — | US | disclosed |
| US-20120035210-A9 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2012-02-09 | — | — | US | disclosed |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-08-26 | — | — | US | disclosed |
| US-5480905-A | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0565732-A1 | BENZODIOXANE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035210-A9 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | PMP22, NPY2R, ADRA2C | MAOB 343/4885MAOA 703/4885DRD2 277/4885 |
| US-20130281486-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | PMP22, NPY2R, ADRA2C | MAOB 308/4885MAOA 576/4885DRD2 230/4885 |
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | KRAS, NRAS, HRAS | MAOB 4420/4885MAOA 4589/4885DRD2 4814/4885 |
| US-20140179926-A1 | 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | PMP22, NPY2R, ADRA2C | MAOB 301/4885MAOA 550/4885DRD2 204/4885 |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | KRAS, NRAS, HRAS | MAOB 4420/4885MAOA 4589/4885DRD2 4814/4885 |
| US-20150336943-A1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HCRTR1, HCRTR2, OXSR1 | MAOB 213/4885MAOA 430/4885DRD2 22/4885 |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | PMP22, NPY2R, ADRA2C | MAOB 343/4885MAOA 703/4885DRD2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.